BRIEF—Novasep opens 27 million euros new viral vector commercial production facility

Novasep, a leading supplier of services and technologies for the life sciences industry, has opened a new 27 million euros ($31.4 million) viral vector production facility in Seneffe, Belgium.

The production of the first current Good Manufacturing Practices (cGMP) batches will start in first-half 2019.

This project, known as Senrise-IV, represents an operational and strategic step forward for Novasep.

This facility features the bioproduction of viral vectors at commercial industrial scale in an integrated manner and with full control of the value creation chain.

To this end, Novasep has doubled its on-site workforce with the creation of 75 positions.

The facility will feature two cGMP production lines: one dedicated to adherence cell culture for viral vectors in moderate quantities – to treat certain rare diseases or for lower dose indications – and one for suspension cell culture with bioreactors of 50 to 2000 liters to produce larger quantities.

This equipment is designed to meet the growing demand of biopharmaceutical companies worldwide.